- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02635724
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
February 26, 2021 updated by: BioCryst Pharmaceuticals
A Phase 3, Multicenter, Single-arm, Open-label, Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of Intravenous Peramivir in Elderly Subjects With Acute Uncomplicated Influenza Infection and in Subjects With Acute Uncomplicated Influenza Infection at Higher Risk for Influenza Complications
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute uncomplicated influenza infection at higher risk for influenza complications.
All subjects will receive IV peramivir.
Study Overview
Study Type
Interventional
Enrollment (Actual)
74
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Brooksville, Florida, United States
- Peramivir Investigational Site
-
Lakeland, Florida, United States
- Peramivir Investigational Site
-
Miami, Florida, United States
- Peramivir Investigational Site
-
Saint Petersburg, Florida, United States
- Peramivir Investigational Site
-
Tampa, Florida, United States
- Peramivir Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, United States
- Peramivir Investigative Site
-
-
Michigan
-
Detroit, Michigan, United States
- Peramivir Investigative Site
-
-
Ohio
-
Dayton, Ohio, United States
- Peramivir Investigational Site
-
-
Pennsylvania
-
Smithfield, Pennsylvania, United States
- Peramivir Investigative Site
-
-
Texas
-
Houston, Texas, United States
- Peramivir Investigational Site
-
San Antonio, Texas, United States
- Peramivir Investigative Site
-
Splendora, Texas, United States
- Peramivir Investigative Site
-
-
Utah
-
Draper, Utah, United States
- Peramivir Investigational Site
-
Salt Lake City, Utah, United States
- Peramivir Investigational Site
-
South Jordan, Utah, United States
- Peramivir Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A positive influenza Rapid Antigen Test (RAT) and/or a FDA-approved PCR test and at least one clinical sign or symptom consistent with acute influenza infection as listed below OR
- Clinical signs and symptoms consistent with acute influenza infection consisting of an oral temperature ≥ 100°F (37.8°C) with at least one respiratory symptom of at least moderate severity (cough or rhinitis) and at least one constitutional symptom of at least moderate severity (myalgia [aches and pains], headache, feverishness, or fatigue)
- Influenza symptom onset < 48 hours. However, due to historically delayed presentation for medical care in the adult population, approximately 20% of the elderly population may be enrolled with symptoms starting > 48-hours but ≤ 72-hours
Exclusion Criteria:
- Women who plan to breast-feed for the first 48 hours after study drug administration
- Subjects requiring hospital admission to treat medical condition(s) which could represent complications of influenza.
- Recent worsening of any chronic medical condition consistent with complications of influenza
- Current evidence of a bacterial infection requiring antibiotic treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Peramivir
Single dose 600 mg IV injection
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability, as Measured by the Number of Adverse Events.
Time Frame: 14 days
|
Safety was evaluated through assessment of Adverse Events (AEs).
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Exposure of IV Peramivir as Measured by Drug Concentrations up to 3 Hours Post Infusion
Time Frame: up to 3 hours post peramivir infusion
|
Up to 3 plasma samples will be drawn, where possible: immediately following infusion, 30 mins to 1 hr post-infusion & 1 to 3 hrs post-infusion.
Maximum concentration (Cmax), area under the concentration vs. time curve (AUC) from time 0 to 1 hour (AUC0-1), AUC from time 0 to 1.5 hours (AUC0-1.5),
and AUC from time 0 to the last measurable time point (AUC0-last) were calculated in Phoenix® WinNonlin® v6.4.
No summary statistics were reported due to the variation in the infusion time and sampling times.
|
up to 3 hours post peramivir infusion
|
Time to Resolution of Fever
Time Frame: 14 days
|
Time for fever resolution based on subject diary record of temperature recorded twice daily.
A subject had resolution of fever if he/she had an oral temperature < 37.4°C/99.4°F
oral and no antipyretic medications were taken for at least 12 hours.
The time to resolution of fever was estimated for each age group and overall using the Kaplan-Meier method with temperature and symptom relief medication information obtained from the Subject Diary data.
Subjects who did not have resolution of fever were censored at the time of their last non-missing post-baseline temperature assessment.
|
14 days
|
Time to Resolution of Influenza Symptoms
Time Frame: 14 days
|
Subjects were asked to provide an assessment of 7 influenza symptoms (cough, sore throat, nasal congestion, myalgia [aches and pains], headache, feverishness, and fatigue) on a 4-point severity scale (0, absent; 1, mild; 2, moderate; 3, severe) beginning at Screening then twice daily beginning on Day 1 through to Day 13, and prior to the subject's clinic visit on Day 14.
Once all symptoms were scored a 0 or 1 for at least 48 hours, recordings were discontinued.
The time to alleviation of symptoms, defined as the time from initiation of study drug until the start of the 21.5-hour period (24 hours less 10%), where all symptoms of influenza were recorded as none (0) or mild (1), was estimated overall and for each age group using the Kaplan-Meier method.
|
14 days
|
Changes in Influenza Virus Titer in Nasopharyngeal Samples in Response to Treatment.
Time Frame: Change from baseline assessed on days 3, 7 and 14.
|
Change in influenza viral titers was defined as the time-weighted change from Baseline in log_10 tissue culture infective dose_50 (TCID50/mL) and was summarized for each treatment group.
|
Change from baseline assessed on days 3, 7 and 14.
|
Time to Reduction in Viral Shedding
Time Frame: 14 days
|
Assessment of viral shedding in bilateral, mid-nasal swab specimens taken at baseline and then on Day 3, 7 and 14.
|
14 days
|
Incidence of Influenza-related Complications
Time Frame: 14 days
|
Study personnel evaluated the subject at Screening and Days 3, 7, and 14 for the presence of clinical signs and/or symptoms of the following influenza-related complications: Sinusitis, Otitis media, Bronchitis & Pneumonia.
Note that subjects with clinical signs and/or symptoms consistent with bacterial infections, including otitis media, bronchitis, sinusitis, and/or pneumonia at Screening, were not eligible for enrollment in this study.
If an influenza-related complication was suspected, then a targeted physical examination was to be conducted to confirm the presence or absence of the influenza-related complication.
|
14 days
|
Time to Return to Usual Activities
Time Frame: 14 days
|
The ability to perform usual daily activities was assessed on a VAS (Visual Analogue Scale), where 0 indicates "unable to perform usual activities at all" and 10 indicates "able to perform usual activities.".
The time to return to usual activities was the number of days from initiation of study drug until the subject recorded a rating of 10 (able to perform all usual activities fully) on the VAS; this was estimated for each age group and overall using the Kaplan-Meier method.
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Carol Clark, MD, Prof., Dept. of Emergency Medicine, Oakland University, William Beaumont School of Medicine, Royal Oak, MI
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2015
Primary Completion (Actual)
April 1, 2018
Study Completion (Actual)
September 1, 2018
Study Registration Dates
First Submitted
December 17, 2015
First Submitted That Met QC Criteria
December 18, 2015
First Posted (Estimate)
December 21, 2015
Study Record Updates
Last Update Posted (Actual)
March 23, 2021
Last Update Submitted That Met QC Criteria
February 26, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCX1812-306
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Avian Influenza | H1N1 InfluenzaUnited States
Clinical Trials on Peramivir
-
BioCryst PharmaceuticalsWithdrawn
-
BioCryst PharmaceuticalsCompletedInfluenzaUnited States, Canada
-
BioCryst PharmaceuticalsCompletedInfluenzaUnited States, Australia, Canada, Hong Kong, New Zealand, Singapore, South Africa
-
BioCryst PharmaceuticalsDepartment of Health and Human ServicesTerminatedCough | Fever | Headache | Nasal Congestion | Seasonal Influenza | Sore ThroatUnited States, Poland, Ukraine, Germany, Belgium, Argentina, Israel, Bulgaria, Serbia, South Africa, Brazil, Canada, Chile, Peru, Russian Federation, Hungary, Czech Republic, India, United Kingdom, Latvia, Bosnia and Herzegovina, ... and more
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of OxfordRecruitingInfluenza | Influenza, HumanThailand
-
BioCryst PharmaceuticalsCompletedAcute, Uncomplicated Human InfluenzaUnited States, Australia, New Zealand, South Africa
-
National Institute of Allergy and Infectious Diseases...Withdrawn
-
BioCryst PharmaceuticalsTerminated
-
BioCryst PharmaceuticalsCompletedInfluenzaUnited States, South Africa